07:57 AM EST, 02/10/2025 (MT Newswires) -- Nektar Therapeutics ( NKTR ) said Monday the US Food and Drug Administration has granted fast-track designation to its experimental drug, rezpegaldesleukin, for treating moderate-to-severe atopic dermatitis in certain adults and pediatric patients aged 12 and older.

The company said it plans to announce data from the induction period of its phase 2b study in the second quarter of this year.